167 related articles for article (PubMed ID: 15685823)
21. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Alexopoulos A; Tryfonopoulos D; Karamouzis MV; Gerasimidis G; Karydas I; Kandilis K; Stavrakakis J; Stavrinides H; Georganta C; Ardavanis A; Rigatos G
Ann Oncol; 2004 Jan; 15(1):95-9. PubMed ID: 14679126
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Hamm JT; Wilson JW; Rastogi P; Lembersky BC; Tseng GC; Song YK; Kim W; Robidoux A; Raymond JM; Kardinal CG; Shalaby IA; Ansari R; Paik S; Geyer CE; Wolmark N;
Clin Breast Cancer; 2008 Jun; 8(3):257-63. PubMed ID: 18650156
[TBL] [Abstract][Full Text] [Related]
23. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
[TBL] [Abstract][Full Text] [Related]
24. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
25. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
Natoli C; Cianchetti E; Tinari N; Angelucci D; Grassadonia A; Zilli M; Ficorella C; Ricevuto E; Grossi S; De Tursi M; Carella C; Rispoli AI; Iacobelli S
Ann Oncol; 2007 Jun; 18(6):1015-20. PubMed ID: 17369601
[TBL] [Abstract][Full Text] [Related]
27. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Mavroudis D; Malamos N; Polyzos A; Kouroussis Ch; Christophilakis Ch; Varthalitis I; Androulakis N; Kalbakis K; Milaki G; Georgoulias V;
Oncology; 2004; 67(3-4):250-6. PubMed ID: 15557786
[TBL] [Abstract][Full Text] [Related]
28. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
Pignata S; Varriale E; Casella G; Iodice F; De Placido G; Perrone F; Tramontana F; Ricchi P; De Vivo R; Costanzo R; Vernaglia A; Tramontana S
Ann Oncol; 2000 May; 11(5):613-6. PubMed ID: 10907958
[TBL] [Abstract][Full Text] [Related]
30. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
Lopez M
Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
[TBL] [Abstract][Full Text] [Related]
31. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Daz M; Miró C; Lobo F
Semin Oncol; 2004 Apr; 31(2 Suppl 5):31-6. PubMed ID: 15199530
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer.
Yardley DA
Semin Oncol; 2004 Apr; 31(2 Suppl 5):37-44. PubMed ID: 15199531
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Levy C; Fumoleau P
Cancer Treat Rev; 2005; 31 Suppl 4():S17-22. PubMed ID: 16360543
[TBL] [Abstract][Full Text] [Related]
36. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
Thuerigen O; Schneeweiss A; Toedt G; Warnat P; Hahn M; Kramer H; Brors B; Rudlowski C; Benner A; Schuetz F; Tews B; Eils R; Sinn HP; Sohn C; Lichter P
J Clin Oncol; 2006 Apr; 24(12):1839-45. PubMed ID: 16622258
[TBL] [Abstract][Full Text] [Related]
37. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Laufman LR; Spiridonidis CH; Pritchard J; Roach R; Zangmeister J; Larrimer N; Moore T; Segal M; Jones J; Patel T; Gutterman L; Carman L; Colborn D; Kuebler JP
Ann Oncol; 2001 Sep; 12(9):1259-64. PubMed ID: 11697837
[TBL] [Abstract][Full Text] [Related]
38. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
[TBL] [Abstract][Full Text] [Related]
40. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]